May 6, 2022

News provided by Share this article Share this article ANN ARBOR, Mich., April 20, 2022 /PRNewswire/ -- NOTA announces its 1st closing of financing from Pegasus Tech Ventures, a global venture capital firm based in Silicon Valley as part of a planned $5M financing. This adds to the $4.2M the Company has already secured from NIH for its nitric oxide (NO) generating technologies. The Company is also seeking other investors to complete the overall financing. NOTA has two patented platform technologies that inexpensively generate NO "on-demand." The Company's systems are compact and suitable for the hospital, clinic, and in-home / ambulatory use. NOTA's NOGEN™ System uses an electrochemical method to generate NO for months on end, while its LANOR™ System uses light to produce NO from a proprietary chemically coated filmstrip that is well suited to emergency and in-home use. NOTA Laboratories receives funding from Pegasus Tech Ventures of Silicon Valley. Nitric oxide's biological importance was only discovered in the early 1990s and has since garnered a tremendous amount of attention from biomedical researchers for a wide range of applications. NO is produced in our sinuses, blood vessels and in other parts of the body where it acts as an antiviral, antibacterial, vasodilator, anti-inflammatory and antithrombotic. It is a key component of the body's first line of immune response to infection. NOTA's systems can be used to augment the body's NO production for potentially life-saving applications like persistent pulmonary hypertension of the newborn (PPHN), reducing systemic inflammation response syndrome (SIRS) during cardiopulmonary bypass (CPB) surgery, for use in treating respiratory infections and inflammatory conditions, and for chronic obstructive pulmonary disease (COPD). Malcolm Kahn, NOTA's CEO said "We are excited about our collaboration with Pegasus Tech Ventures that brings both investment and the potential for broader corporate partner engagement in the future." Bill Reichert, Partner from Pegasus Tech Ventures sees NOTA as "an important addition to our growing portfolio in the medical market segment". NOTA's other proprietary NO delivery technologies, which are single-use infection fighting disposables, including a sinus spray, a sachet that can be placed into a face mask and two catheter products, have been spun out into a separately run startup called NOxygen Therapeutics. Pegasus Tech Ventures  is a global venture capital firm based in Silicon Valley with $2 Billion in assets under management. Pegasus offers intellectual and financial capital to emerging technology companies around the world. In addition to offering institutional investors a top-tier venture capital investment approach, Pegasus also offers a unique Venture Capital-as-a-Service (VCaaS) model for large, global corporations that wish to partner with cutting-edge technology startups. For more information about Pegasus, please check out https://www.pegasustechventures.com . Malcolm Kahn